{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:30:51Z","timestamp":1791477051543,"version":"4.3.4"},"reference-count":19,"publisher":"Society of Nuclear Medicine","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,10,9]]},"published-print":{"date-parts":[[2026,1]]},"DOI":"10.2967\/jnumed.125.270508","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T20:25:15Z","timestamp":1763670315000},"page":"132-138","source":"Crossref","is-referenced-by-count":5,"title":["Radiolabeling of CHX-A\u2033-DTPA-Antibody Conjugates with [\n                    <sup>89<\/sup>\n                    Zr]ZrCl\n                    <sub>4<\/sub>"],"prefix":"10.2967","volume":"67","author":[{"given":"Serge K.","family":"Lyashchenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio V.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kali","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hijin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas M.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga Vara Kishore","family":"Pillarsetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"2026010206300800000_67.1.132.1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.172031"},{"key":"2026010206300800000_67.1.132.2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2967\/jnumed.118.222844","article-title":"Imaging patients with metastatic castration-resistant prostate cancer using 89Zr-DFO-MSTP2109A anti-STEAP1 antibody","volume":"60","author":"Carrasquillo","year":"2019","journal-title":"J Nucl Med."},{"key":"2026010206300800000_67.1.132.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3667"},{"key":"2026010206300800000_67.1.132.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266392"},{"key":"2026010206300800000_67.1.132.5","first-page":"1271","article-title":"89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies","volume":"44","author":"Verel","year":"2003","journal-title":"J Nucl Med."},{"key":"2026010206300800000_67.1.132.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2009.05.007"},{"key":"2026010206300800000_67.1.132.7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s41181-024-00258-y","article-title":"Good practices for 89Zr radiopharmaceutical production and quality control","volume":"9","author":"Wuensche","year":"2024","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2026010206300800000_67.1.132.8","first-page":"1297","article-title":"89Zr for antibody labeling and positron emission tomography","volume":"23","author":"Link","year":"1986","journal-title":"J. Labelled Compd. Radiopharm."},{"key":"2026010206300800000_67.1.132.9","doi-asserted-by":"publisher","DOI":"10.1016\/0883-2889(92)90170-J"},{"key":"2026010206300800000_67.1.132.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-006-0160-0"},{"key":"2026010206300800000_67.1.132.11","doi-asserted-by":"crossref","first-page":"108943","DOI":"10.1016\/j.nucmedbio.2024.108943","article-title":"[89Zr]ZrCl4 for direct radiolabeling of DOTA-based precursors","volume":"136-137","author":"Lyashchenko","year":"2024","journal-title":"Nucl Med Biol."},{"key":"2026010206300800000_67.1.132.12","doi-asserted-by":"crossref","first-page":"12883","DOI":"10.1039\/D2SC04522B","article-title":"Zr4+ solution structures from pair distribution function analysis","volume":"13","author":"Kl\u00f8ve","year":"2022","journal-title":"Chem Sci."},{"key":"2026010206300800000_67.1.132.13","doi-asserted-by":"crossref","unstructured":"Tendler S Dunphy MP Agee M . First-in-human imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate [preprint]. https:\/\/www.medrxiv.org\/content\/10.1101\/2024.01.10.24301109v1.full. Accessed October 30, 2025.","DOI":"10.1101\/2024.01.10.24301109"},{"key":"2026010206300800000_67.1.132.14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nucmedbio.2019.04.005","article-title":"A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals","volume":"71","author":"Sharma","year":"2019","journal-title":"Nucl Med Biol."},{"key":"2026010206300800000_67.1.132.15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11307-023-01868-9","article-title":"MIB guides: preclinical radiopharmaceutical dosimetry","volume":"26","author":"Carter","year":"2024","journal-title":"Mol Imaging Biol."},{"key":"2026010206300800000_67.1.132.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268011"},{"key":"2026010206300800000_67.1.132.17","first-page":"689","article-title":"Bone marrow dosimetry for radioimmunotherapy: theoretical considerations","volume":"34","author":"Sgouros","year":"1993","journal-title":"J Nucl Med."},{"key":"2026010206300800000_67.1.132.18","doi-asserted-by":"publisher","DOI":"10.1021\/mp500323d"},{"key":"2026010206300800000_67.1.132.19","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.7150\/thno.39089","article-title":"The influence of glycans-specific bioconjugation on the Fc\u03b3RI binding and in\u00a0vivo performance of 89Zr-DFO-pertuzumab","volume":"10","author":"Vivier","year":"2020","journal-title":"Theranostics."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.270508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T14:30:32Z","timestamp":1767364232000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.270508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,2]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.2967\/jnumed.125.270508"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.270508","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}